Pfizer To Issue Trovan I.V. "Dear Doctor" Letter With Labeling Changes
Executive Summary
Pfizer will notify health care professionals of Trovan I.V. labeling changes due to incompatibility with .9% sodium chloride injection via a "Dear Doctor" letter after receiving a warning letter from FDA.
You may also be interested in...
Roxane's Cafcit Approval Based On Post-Hoc Analysis Of Phase III Trial
FDA approved Roxane's Cafcit (caffeine citrate) on Sept. 21 based on a literature review and a post-hoc analysis of secondary endpoints from a Phase III trial.
Roxane's Cafcit Approval Based On Post-Hoc Analysis Of Phase III Trial
FDA approved Roxane's Cafcit (caffeine citrate) on Sept. 21 based on a literature review and a post-hoc analysis of secondary endpoints from a Phase III trial.
Adverse event reports
Pfizer "has been implementing remedial actions designed to remedy" issues raised in an April 1996 FDA warning letter, the company's annual report discloses. The letter concerned "timeliness and completeness of required post-marketing reports" and corrective action was discussed with the agency in 1997. "A full examination of the progress made by the company in this area will occur in 1999," the annual report states. Pfizer received an FDA warning letter in December regarding incomplete formulation warnings from Trovan clinical trials (1"The Pink Sheet" Jan. 11, p. 13)